|

Tezepelumab Clinical Trials

7 actively recruiting trials across 4 locations

▼ -1 trial since August 2026

Also known as: MEDI9929 and AMG157, TEZSPIRE

Pipeline

Phase 3: 4Phase 4: 1

Top Sponsors

  • AstraZeneca5
  • University of Leeds1
  • University of Alberta1

Indications

  • Asthma5
  • Severe Asthma3
  • Chronic Obstructive Pulmonary Disease (COPD)2
  • COPD2
  • MACE1

Other3 trials

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Phase 3
Physical Activity Promotion and Clinical Remission in Severe Asthma
N/A
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
Phase 4

Cullman, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Research Site

Phase 3

Foley, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Research Site

Phase 3

Montgomery, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Research Site

Phase 3

Wilmington, Delaware1 trial

Tezspire Cardiac Events PASS

Healthcare Integrated Research Database (HIRD)

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.